Evaluation of the Effects of Meal Type and Acid ‐Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist
This study suggests that caution should be exercised when cilofexor is administered with ARAs under fed conditions; coadministration of cilofexor (100 or 30 mg) with ARAs under fasting conditions is not recommended with the current clinical trial formulations.
Source: Clinical Pharmacology in Drug Development - Category: Drugs & Pharmacology Authors: Elijah J. Weber,
Islam R. Younis,
Lulu Wang,
Deqing Xiao,
William T. Barchuk,
Ahmed A. Othman Tags: Original Article Source Type: research
More News: Clinical Trials | Drugs & Pharmacology | Famotidine | High Fat | Omeprazole | Prilosec | Study